drugset / Trial / NCT02248428
Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
Due to economic reasons, thalidomide is still widely used as a first line drug for Multiple Myeloma patients in China. However,the efficacy of CTd is still lower than the therapeutic regimens with new drugs. Clarithromycin may have partly efficacy in association with steroids and thalidomide for Multiple Myeloma patients. This multicenter, randomized, phase 3 clinical trial is proposed to explore whether clarithromycin could potentiate responsiveness of CTd (Cyclophosphamide, Thalidomide and Dexamethasone) regimen in Newly Diagnosed Multiple Myeloma patients. The trial will also evaluate the side effects caused by the combination of these drugs.
Timeline
- Start
- 2012-04
- Primary completion
- 2019-09
- Completion
- 2020-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | Oral |
| Background | Cyclophosphamide | Other / unclassified | 300 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 40 mg | Oral |
| Background | Thalidomide | Other / unclassified | 100 mg | Oral |
| Background | Thalidomide | Other / unclassified | 200 mg | Oral |